Spark Therapeutics (ONCE): Reiterated Buy After Gene Therapy Panel - Cantor Fitzgerald

Cantor Fitzgerald analyst, Elemer Piros, reiterated his Buy rating on Spark Therapeutics (NASDAQ: ONCE) after he conducted a panel discussion, including the competitive landscape in gene therapy, at Cantor Fitzgerald’s 2nd Annual Healthcare Conference.

The analyst stated: "While the gene to be corrected may indeed be identical, the components of its delivery (vector, promoter, capsid) and the efficiency of gene expression is indeed different in all cases. The "winner" from the clinical perspective will be selected based on the level of correction, its clinical benefit and the durability of such benefit. The consistency of correction reported from the first four patients in the hemophilia B program places Spark in the lead, for the time being, in our view. Durability is perhaps even a more important consideration, from both the regulatory and the reimbursement perspectives. Should someone, such as Baxalta, get to market first, regulators may require a second product to show superiority either in efficacy or safety, before approving it for an orphan indication."

price target of $94.00

For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.

Shares of Spark Therapeutics closed at $52.92 yesterday.

You May Also Be Interested In

• AGNC Investment Corp (AGNC) PT Lowered to $10.25 at Jones Trading
• Verona Pharma (VRNA) PT Raised to $34 at BTIG
• JetBlue Airways (JBLU) PT Lowered to $6 at TD Cowen